ReviewJournal of bone oncology2023
Adamantinoma: A review of the current literature.
Review in Journal of bone oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Liquid nitrogen-treated recycled autograft for reconstruction of a large tibial defect following wide resection of adamantinoma: a case report.International journal of surgery case reports · 2026Article
- Histological Dedifferentiation in Recurrent Adamantinoma of the Tibia: A Case Report.Journal of orthopaedic case reports · 2025Article
- Bone lesions of the tibia: Multimodal iconographic review and diagnostic algorithms, Part 1: Diagnostic algorithms, dysplasia and diaphyseal lesions.European journal of radiology open · 2025Review
- Meta-analysis of 65 Adamantinoma case reports: Unveiling symptomatology, demographics, and treatment outcomes in contrast to prior understandings.Journal of orthopaedics · 2025Review
- Dedifferentiated adamantinoma of long bones: a case report and literature review.Frontiers in oncology · 2025Article
- Radical total pelvic exenteration with concomitant right nephrectomy in the management of recurrent endometrioid ovarian adenocarcinoma: A case report and literature review.Clinical case reports · 2024Article
- Rare Case of Recurrent Adamantinoma of the Tibia: Limited Efficacy of Pazopanib as a Standalone Treatment.The American journal of case reports · 2024Article
- Tibial Adamantinoma: A Case Report from a Resource-Limited-Setting.International medical case reports journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adamantinoma is a rare primary low-grade malignant tumour of the appendicular skeleton most commonly found in the tibia. It has an indolent course, with local recurrences and lung metastases occurring over a protracted duration. There have been several suggestions pertaining to a vascular origin in the literature, however, histogenesis remains unclear. Currently, guidelines are not available pertaining to clinical management. This paper presents an overview of the current literature regarding this unusual malignancy. It also explores disease etiology and acknowledges the benefits and challenges of investigations pertaining to diagnosis. It recognizes a paucity of recommendations regarding appropriate surveillance and follow up. This review aims to assist clinicians in the building of a consensus opinion for optimal adamantinoma case management under current circumstances where formal guidelines do not exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.